Table 4 Univariate analyses of the impact on overall survival in patients with CN-AML who received intensive induction chemotherapy

Age, years

0.001 ^*

  60 or younger

66

32.2

  Older than 60

22

4.5

WBC

0.469

  50000/uL or less

49

31.433

  Greater than 50000/uL

37

13

BDH2

0.007 ^*

  Lower expression

46

53.667

  Higher expression

40

9

CEBPA

0.755

  Double mutation

9

31.433

  Single mutation

16

53.667

  No mutation

61

16.267

NPM1

0.179

  Mutated

28

10.4

  Wild

58

32.2

FLT3- ITD^-

<0.001^*

  Mutated

17

4.767

  Wild

70

48.633

FLT3- TKD

0.596

  Mutated

7

13.00

  Wild

79

18.567

NPM1/FLT3- ITD

0.314

  NPM1⁺/FLT3- ITD^-

15

NR

  Others

71

15.067

IDH1 ^b

0.796

  Mutated

3

22.21

  Wild

61

27.055

IDH2 ^b

0.749

  Mutated

4

21.91

  Wild

60

27.16

DNMT3A ^b

0.508

  Mutated

11

32.58

  Wild

53

25.63

MLL ^b

0.178

  Mutated

5

12.63

  Wild

59

13.12

BDH2 ^low /FLT3-ITD

<0.001^*

  BDH2^low/FLT3-ITD^{wild type}

40

722.16

  BDH2^low/FLT3-ITD^mutation

5

519.73

  BDH2^high/FLT3-ITD^{wild type}

27

371.56

  BDH2^high/FLT3-ITD^mutation

13

182.27